Delafloxacin: what does a new fluoroquinolone offer?

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Delafloxacin is a novel anionic fluoroquinolone with unique physicochemical properties.
• It exhibits dual-targeted inhibition of bacterial DNA gyrase and topoisomerase IV.
• This dual action may contribute to low rates of spontaneous mutations.

Purpose of the Study:

• To evaluate the in vitro activity and pharmacokinetic profile of delafloxacin.
• To assess its efficacy in treating various bacterial infections.
• To explore its potential in challenging infection types like biofilm-related and polymicrobial infections.

Main Methods:

• In vitro susceptibility testing against Gram-negative and Gram-positive bacteria, including resistant strains.
• Pharmacokinetic studies demonstrating linear pharmacokinetics and a wide volume of distribution.
• Analysis of clinical trial data for approved indications: acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia.

Main Results:

• Potent in vitro activity against a broad spectrum of bacteria, including fluoroquinolone-resistant strains and MRSA.
• Effective concentration-dependent killing and favorable pharmacokinetic profile.
• Well-tolerated with a low drug-drug interaction profile in clinical trials.

Conclusions:

• Delafloxacin is a valuable addition to the antibiotic arsenal due to its broad spectrum and unique activity profile.
• Its efficacy in acidic environments and biofilms suggests potential for treating difficult infections.
• Approved for skin infections and pneumonia, it shows promise for other challenging bacterial infections.